|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After analyzing the RNA-Seq data of PTC patients from the Cancer Genomic Atlas, 497 differentially expressed PTC genes were found to be associated with HT, of which protein tyrosine phosphatase receptor type C (PTPRC), KIT, and COL1A1 were associated with tumor size and lymph node metastasis (p < 0.05).
|
31686862 |
2019 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this report a further case of SV-PTC is described which was associated to Hashimoto's thyroiditis, a finding never described in the cytological literature up to now for SV-PTC; this association created further differential diagnostic problems.The neoplasm displayed RET-PTC1 fusion.
|
30659000 |
2019 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the association between RET/PTC rearrangements and thyroid hormone homeostasis, and explored whether concomitant diseases such as nodular goiter and Hashimoto's thyroiditis influenced this association.
|
27802347 |
2016 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular studies have identified activation of the RET/PTC rearrangement-induced MAPK signaling pathway as the driving force in the development of PTC in the context of HT.
|
20738253 |
2010 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating BRAF point mutations, RAS aberrations, and RET rearrangements are mutually exclusive events in the oncogenesis of papillary thyroid carcinoma, and RET rearrangements have been previously described in dominant nodules of HT.
|
20012784 |
2010 |
|
Hashimoto Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To determine whether thyrocytes showing oxyphil cell metaplasia in HT also express RET, RAS, and ERK proteins, which are associated with PTC.
|
17900235 |
2007 |
|
Hashimoto Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In PTC cells, HT oxyphil cells, and normal thyrocytes, the frequency of high RET expression was 23/70 (32.9%), 36/57 (63.2%), and 1/57 (1.8%) (p = 0.000); that of high nuclear localized RAS expression (nuclearRAS) was 65/71 (91.5%), 52/58 (89.7%), and 5/58 (8.6%) (p = 0.000); and that of high ERK expression was 38/70 (54.3%), 34/61 (55.7%), and 0/61 (0.0%) (p = 0.000), respectively.
|
17900235 |
2007 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low-level RET/PTC recombination occurs in nonneoplastic follicular cells in HT and in a subset of papillary thyroid carcinomas.
|
16595592 |
2006 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
From the PTC patients, one had MNG and fvPTC, one MNG, lymphocytic thyroiditis and papillary pattern of PTC, one lymphocytic thyroiditis and fvPTC, and one MNG and papillary pattern of PTC.
|
16405407 |
2005 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure.
|
15472167 |
2004 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
These results suggest that, if the association between HT and thyroid cancer exists, its molecular basis is different from RET/PTC rearrangement.
|
11927965 |
2002 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The finding of the RET-PTC translocations in CLT has been reported by two independent groups of investigators, suggesting that the areas of nuclear atypia in CLT are neoplastic rather than reactive.
|
12665650 |
2002 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the RT-PCR technique, we observed a RET/PTC rearrangement in the carcinomatous areas of patients of both families: PTC1 in family 1 and PTC3 in family 2 and a RET/PTC rearrangement in non-malignant thyroid tissue with LT in family 2.
|
11747322 |
2001 |